A Primary Prevention Clinical Risk Score Model for Patients With Brugada Syndrome (BRUGADA-RISK).


Journal

JACC. Clinical electrophysiology
ISSN: 2405-5018
Titre abrégé: JACC Clin Electrophysiol
Pays: United States
ID NLM: 101656995

Informations de publication

Date de publication:
02 2021
Historique:
received: 02 07 2020
revised: 13 08 2020
accepted: 14 08 2020
entrez: 19 2 2021
pubmed: 20 2 2021
medline: 19 8 2021
Statut: ppublish

Résumé

The goal of this study was to develop a risk score model for patients with Brugada syndrome (BrS). Risk stratification in BrS is a significant challenge due to the low event rates and conflicting evidence. A multicenter international cohort of patients with BrS and no previous cardiac arrest was used to evaluate the role of 16 proposed clinical or electrocardiogram (ECG) markers in predicting ventricular arrhythmias (VAs)/sudden cardiac death (SCD) during follow-up. Predictive markers were incorporated into a risk score model, and this model was validated by using out-of-sample cross-validation. A total of 1,110 patients with BrS from 16 centers in 8 countries were included (mean age 51.8 ± 13.6 years; 71.8% male). Median follow-up was 5.33 years; 114 patients had VA/SCD (10.3%) with an annual event rate of 1.5%. Of the 16 proposed risk factors, probable arrhythmia-related syncope (hazard ratio [HR]: 3.71; p < 0.001), spontaneous type 1 ECG (HR: 3.80; p < 0.001), early repolarization (HR: 3.42; p < 0.001), and a type 1 Brugada ECG pattern in peripheral leads (HR: 2.33; p < 0.001) were associated with a higher risk of VA/SCD. A risk score model incorporating these factors revealed a sensitivity of 71.2% (95% confidence interval: 61.5% to 84.6%) and a specificity of 80.2% (95% confidence interval: 75.7% to 82.3%) in predicting VA/SCD at 5 years. Calibration plots showed a mean prediction error of 1.2%. The model was effectively validated by using out-of-sample cross-validation according to country. This multicenter study identified 4 risk factors for VA/SCD in a primary prevention BrS population. A risk score model was generated to quantify risk of VA/SCD in BrS and inform implantable cardioverter-defibrillator prescription.

Sections du résumé

OBJECTIVES
The goal of this study was to develop a risk score model for patients with Brugada syndrome (BrS).
BACKGROUND
Risk stratification in BrS is a significant challenge due to the low event rates and conflicting evidence.
METHODS
A multicenter international cohort of patients with BrS and no previous cardiac arrest was used to evaluate the role of 16 proposed clinical or electrocardiogram (ECG) markers in predicting ventricular arrhythmias (VAs)/sudden cardiac death (SCD) during follow-up. Predictive markers were incorporated into a risk score model, and this model was validated by using out-of-sample cross-validation.
RESULTS
A total of 1,110 patients with BrS from 16 centers in 8 countries were included (mean age 51.8 ± 13.6 years; 71.8% male). Median follow-up was 5.33 years; 114 patients had VA/SCD (10.3%) with an annual event rate of 1.5%. Of the 16 proposed risk factors, probable arrhythmia-related syncope (hazard ratio [HR]: 3.71; p < 0.001), spontaneous type 1 ECG (HR: 3.80; p < 0.001), early repolarization (HR: 3.42; p < 0.001), and a type 1 Brugada ECG pattern in peripheral leads (HR: 2.33; p < 0.001) were associated with a higher risk of VA/SCD. A risk score model incorporating these factors revealed a sensitivity of 71.2% (95% confidence interval: 61.5% to 84.6%) and a specificity of 80.2% (95% confidence interval: 75.7% to 82.3%) in predicting VA/SCD at 5 years. Calibration plots showed a mean prediction error of 1.2%. The model was effectively validated by using out-of-sample cross-validation according to country.
CONCLUSIONS
This multicenter study identified 4 risk factors for VA/SCD in a primary prevention BrS population. A risk score model was generated to quantify risk of VA/SCD in BrS and inform implantable cardioverter-defibrillator prescription.

Identifiants

pubmed: 33602402
pii: S2405-500X(20)30819-7
doi: 10.1016/j.jacep.2020.08.032
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

210-222

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Funding Support and Author Disclosures Dr. Lambiase is supported by the Stephen Lyness Memorial Fund, UCLH Biomedicine National Institutes of Health Research, Barts Biomedical Research Centre; and has obtained research grants and speaker fees from Medtronic, Abbott, and Boston Scientific. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Shohreh Honarbakhsh (S)

The Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom.

Rui Providencia (R)

The Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom.

Jorge Garcia-Hernandez (J)

Farr Institute of Health Informatics Research, University College London, London, United Kingdom.

Claire A Martin (CA)

Royal Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom.

Ross J Hunter (RJ)

The Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom.

Wei Y Lim (WY)

The Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom.

Claire Kirkby (C)

The Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom.

Adam J Graham (AJ)

The Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom.

Ardalan Sharifzadehgan (A)

Cardiology Department, European Georges Pompidou Hospital, Paris, France; Paris Descartes University, Paris, France; Paris Cardiovascular Research Center (INSERM U970), Paris, France.

Victor Waldmann (V)

Cardiology Department, European Georges Pompidou Hospital, Paris, France; Paris Descartes University, Paris, France; Paris Cardiovascular Research Center (INSERM U970), Paris, France.

Eloi Marijon (E)

Cardiology Department, European Georges Pompidou Hospital, Paris, France; Paris Descartes University, Paris, France; Paris Cardiovascular Research Center (INSERM U970), Paris, France.

Carmen Munoz-Esparza (C)

Inherited Cardiac Disease Unit, University Hospital Virgen Arrixaca, Murcia, Spain.

Javier Lacunza (J)

Inherited Cardiac Disease Unit, University Hospital Virgen Arrixaca, Murcia, Spain.

Juan Ramón Gimeno-Blanes (JR)

Inherited Cardiac Disease Unit, University Hospital Virgen Arrixaca, Murcia, Spain.

Benedicte Ankou (B)

Rhythmology Department, Hôpital Cardiovasculaire Louis Pradel, Claude Bernard University, Lyon, France.

Philippe Chevalier (P)

Rhythmology Department, Hôpital Cardiovasculaire Louis Pradel, Claude Bernard University, Lyon, France.

Nátalia Antonio (N)

Cardiology Department, Coimbra Hospital and University Centre, Coimbra, Portugal.

Luís Elvas (L)

Cardiology Department, Coimbra Hospital and University Centre, Coimbra, Portugal.

Silvia Castelletti (S)

Cardiology Department, Coimbra Hospital and University Centre, Coimbra, Portugal.

Lia Crotti (L)

Laboratory of Cardiovascular Genetics, Center for Cardiac Arrhythmias of Genetic Origin, IRCCS Istituto Auxologico, Italiano, Milan, Italy.

Peter Schwartz (P)

Laboratory of Cardiovascular Genetics, Center for Cardiac Arrhythmias of Genetic Origin, IRCCS Istituto Auxologico, Italiano, Milan, Italy.

Mauricio Scanavacca (M)

Arritmia, Instituto do Coracao, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.

Francisco Darrieux (F)

Arritmia, Instituto do Coracao, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.

Luciana Sacilotto (L)

Arritmia, Instituto do Coracao, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.

Johanna Mueller-Leisse (J)

Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.

Christian Veltmann (C)

Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.

Alessandro Vicentini (A)

Policlinico San Matteo Pavia Fondazione IRCCS, Pavia, Italy.

Andrea Demarchi (A)

Policlinico San Matteo Pavia Fondazione IRCCS, Pavia, Italy.

Nuno Cortez-Dias (N)

Department of Cardiology, Santa Maria University Hospital, Lisbon Academic Medical Centre and Cardiovascular Centre of the University of Lisbon, Faculty of Medicine, Lisbon, Portugal.

Pedro Silverio Antonio (PS)

Department of Cardiology, Santa Maria University Hospital, Lisbon Academic Medical Centre and Cardiovascular Centre of the University of Lisbon, Faculty of Medicine, Lisbon, Portugal.

João de Sousa (J)

Department of Cardiology, Santa Maria University Hospital, Lisbon Academic Medical Centre and Cardiovascular Centre of the University of Lisbon, Faculty of Medicine, Lisbon, Portugal.

Pedro Adragao (P)

Cardiology Department, Santa Cruz Lisboa Hospital, Lisbon, Portugal.

Diogo Cavaco (D)

Cardiology Department, Santa Cruz Lisboa Hospital, Lisbon, Portugal.

Francisco Morosco Costa (FM)

Cardiology Department, Santa Cruz Lisboa Hospital, Lisbon, Portugal.

Ziad Khoueiry (Z)

Institute Saint Pierre, Perpignan, France.

Serge Boveda (S)

Clinique Pasteur, Toulouse, France.

Mario João Sousa (MJ)

Clinique Pasteur, Toulouse, France.

Zeynab Jebberi (Z)

Clinique Pasteur, Toulouse, France.

Patrick Heck (P)

Royal Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom.

Sarju Mehta (S)

Addenbroke's Hospital, Cambridge, United Kingdom.

Giulio Conte (G)

Cardiac Electrophysiology Unit, Division of Cardiology, Fondazione Cardiocentro Ticino, Lugano, Switzerland.

Tardu Ozkartal (T)

Cardiac Electrophysiology Unit, Division of Cardiology, Fondazione Cardiocentro Ticino, Lugano, Switzerland.

Angelo Auricchio (A)

Cardiac Electrophysiology Unit, Division of Cardiology, Fondazione Cardiocentro Ticino, Lugano, Switzerland.

Martin D Lowe (MD)

The Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom.

Richard J Schilling (RJ)

The Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom.

David Prieto-Merino (D)

Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.

Pier D Lambiase (PD)

The Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom. Electronic address: p.lambiase@ucl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH